A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction
Crossref DOI link: https://doi.org/10.1007/s10198-019-01112-8
Published Online: 2019-09-11
Published Print: 2020-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hansen, Svenn Alexander
Aas, Eline
Solli, Oddvar
Text and Data Mining valid from 2019-09-11
Version of Record valid from 2019-09-11
Article History
Received: 4 December 2018
Accepted: 27 August 2019
First Online: 11 September 2019